IP Library Granted Patent US 9,962,358
Granted Patent B2
US 9,962,358 · App. 15/687,118 · Granted May 8, 2018

Methods of therapeutic monitoring of nitrogen scavenging drugs

Inventors: Bruce Scharschmidt (San Francisco, CA); Masoud Mokhtarani (Walnut Creek, CA)
Assignee: Horizon Therapeutics, LLC
A61K31/235A61K9/0053A61K31/216G01N31/221G01N33/4925G01N33/84G01N2800/04G01N2800/085G01N2800/52Y10T436/175383
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,962,358
App. No.
15/687,118
Granted
May 8, 2018
Kind
B2
Abstract

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Claims (8)

1. A method of treating a urea cycle disorder (UCD) in a pediatric subject in need thereof wherein the pediatric subject has experienced repeated episodes of hyperammonemia and/or chronically elevated ammonia which have impaired the pediatric subject's neurocognitive function, comprising:

administering glyceryl tri-[4-phenylbutyrate] (HPN-100) to the pediatric subject in an amount sufficient to maintain the pediatric subject's fasting plasma ammonia level at less than half the upper limit of normal,

wherein such administration improves neurocognitive function in the pediatric subject.

2. The method of claim 1 , wherein administration of HPN-100 reduces total ammonia burden.

3. The method of claim 1 , wherein administration of HPN-100 reverses the pediatric subject's neurocognitive impairment.

4. The method of claim 1 , wherein neurocognitive function is assessed by BRIEF (Behavior Rating Inventory of Executive Function).

5. The method of claim 1 , wherein the pediatric subject has neonatal presentation of the UCD.

6. The method of claim 1 , wherein the pediatric subject has intercurrent illness.

Assignments (6)
MERGER AND CHANGE OF NAME Recorded Dec 21, 2023
From: HORIZON THERAPEUTICS, LLC; HORIZON ORPHAN LLC
To: HORIZON THERAPEUTICS U.S. HOLDING LLC
Reel/Frame 065928/0608 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0075 →
SECURITY AGREEMENT Recorded Oct 24, 2018
From: HORIZON PHARMA RHEUMATOLOGY LLC; HZNP LIMITED; HORIZON THERAPEUTICS, LLC
To: CITIBANK, N.A.
Reel/Frame 047720/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: MOKHTARANI, MASOUD
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 043578/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: SCHARSCHMIDT, BRUCE
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 043578/0801 →
CHANGE OF NAME Recorded Sep 13, 2017
From: HORIZON THERAPEUTICS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 043849/0748 →
Continuity (9)
Continuation 15457643 · Mar 13, 2017
Continuation 15074691 · Mar 18, 2016
Continuation 14958259 · Dec 3, 2015
Continuation 14816674 · Aug 3, 2015
Continuation 13775000 · Feb 22, 2013
Division 13417137 · Mar 9, 2012
Provisional Application 61564668 · Nov 29, 2011
Provisional Application 61542100 · Sep 30, 2011
Related Publication 20180021291A1 · Jan 25, 2018